SCHEMBL14645121

SCHEMBL14645121

C[C@@H](NC(=O)[C@H](CCCCNC(=O)OC(C)(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCNC(=O)OC(C)(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CCCCNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
GAA P10253 1/20 0.49
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
TDP1 Q9NUW8 4/20 0.42
MAPT P10636 2/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
ATM Q13315 2/20 0.40
MMP1 P03956 1/20 0.40
MMP3 P08254 1/20 0.40
MMP9 P14780 1/20 0.40
NPSR1 Q6W5P4 4/20 0.39
POLB P06746 3/20 0.39
NRP1 O14786 1/20 0.39
CXCR3 P49682 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13254145 1.00 MEN1 (0.49) MEN1KMT2AGAACA1CA2
SCHEMBL31494690 0.94 KMT2A (0.55) MEN1KMT2AGAACA1CA2
SCHEMBL30340151 0.93 MEN1 (0.51) MEN1KMT2AGAACA1CA2
SCHEMBL19971934 0.92 MEN1 (0.53) MEN1KMT2AGAACA1CA2
SCHEMBL31347339 0.92 MEN1 (0.45) MEN1KMT2AGAACA1CA2
SCHEMBL30532183 0.91 MEN1 (0.53) MEN1KMT2AGAACA1CA2
SCHEMBL31347317 0.89 MEN1 (0.47) MEN1KMT2AGAACA1CA2
SCHEMBL30898863 0.88 MEN1 (0.56) MEN1KMT2AGAACA1CA2
SCHEMBL8183191 0.87 MEN1 (0.57) MEN1KMT2AGAACA1CA2
SCHEMBL16909076 0.87 MEN1 (0.57) MEN1KMT2AGAACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357654-B2 Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-01-22 US disclosed
US-20100183642-A1 NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100183642-A1 NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS CD40, CD40LG, TNFSF10 MEN1 4056/4885KMT2A 2653/4885GAA 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.